Bernstein says AstraZeneca R&D engine remains intact

Bernstein analysts said AstraZeneca’s research-and-development engine is still running despite recent setbacks, supporting the company’s long-term outlook. AstraZeneca shares have faced recent pressure as some investors debate prospects.